Search | Clinical Trials Finder

Conditions: Multifocal Motor Neuropathy
Interventions: Immune Globulin Intravenous (human), 10%, 0.25% human albumin solution (Placebo); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Centennial, Colorado + 9 more

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 2 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more

Conditions: Mild Cognitive Impairment
Interventions: Octagam 10%; Biological
Lead sponsor: Sutter Health; Other
Eligibility: 50 Years to 84 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: HYQVIA; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 16 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 30
States / cities: Bakersfield, California • Irvine, California • Redondo Beach, California + 24 more

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Immune Globulin Intravenous (Human), 10% Solution, Immune Globulin Subcutaneous (Human), 20% Solution; Biological · Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 2 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 16
States / cities: Irvine, California • Centennial, Colorado • North Palm Beach, Florida + 13 more

Conditions: Primary Immune Deficiency Disorders (PIDD)
Interventions: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]; Biological
Lead sponsor: ADMA Biologics, Inc.; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more

Conditions: Primary Immune Deficiency Diseases (PIDD)
Interventions: 10% IGIV; Biological
Lead sponsor: Evolve Biologics; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 11
States / cities: Los Angeles, California • Centennial, Colorado • Tampa, Florida + 7 more

Conditions: CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Interventions: Gamunex-C, Xembify; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 4 more

Conditions: Alzheimer's Disease
Interventions: Placebo, octagam 10%; Drug · Biological
Lead sponsor: Octapharma; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hoboken, New Jersey

Conditions: Primary Immune Deficiency
Interventions: GC5107; Biological
Lead sponsor: GC Biopharma Corp; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more

Conditions: Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency
Interventions: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 9
States / cities: Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: TAK-881, HYQVIA; Biological
Lead sponsor: Takeda; Industry
Eligibility: 2 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 15
States / cities: Irvine, California • Walnut Creek, California • Denver, Colorado + 12 more

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP); Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 6
States / cities: New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more

Conditions: End-Stage Renal Disease, Kidney Transplantation
Interventions: Intravenous immune globulin (IVIG); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Middle East Respiratory Syndrome Coronavirus
Interventions: SAB-301, Normal (9%) Saline; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: IgPro10, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: HYQVIA, 0.25% albumin placebo solution with rHuPH20, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 19
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 14 more

Conditions: Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions: Civacir® 10%; Biological
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 15 more

Conditions: Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome
Interventions: Immune Globulin Intravenous (Human), 10%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 24 Months and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • Englewood, Colorado + 8 more

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Recombinant human hyaluronidase + immune globulin intravenous; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 16 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas

Conditions: Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Deficiency Syndromes, Langerhans-Cell Histiocytosis
Interventions: Stem Cell Transplant, Fludarabine, Melphalan, Anti-thymocyte globulin (ATG), Campath 1H, Cyclosporin A, Mycophenolate mofetil, Intravenous immunoglobulin (IVIG); Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 35 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Primary Immunodeficiency
Interventions: IGIV-C 10%, IGSC 20%; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 20
States / cities: Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more

Conditions: Miscarriage, Recurrent, Abortion, Habitual
Interventions: Gamimune N or Gamunex 10%, normal saline; Biological · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Phase 2/3 Study of IGSC, 20% in PIDD

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Study of PlasmaCap IG in Adults and Children With PIDD

A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

Phase 3 IGIV, 10% in Alzheimer´s Disease

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage